Mylan, the company at the centre of the headliner EpiPen price scandal earlier this year have announced the launch of their generic epinephrine auto-injector. Retailing at $300 it sits at half the price of the EpiPen which retailed at £$600.
Announced on the 16th December, the device has now been available on the market since Monday 18th. The generic will be available in 0.3 mg and 0.15 mg dosages at the wholesale price of $300 for a two-pack product.
The EpiPen is used to treat severe allergic reactions in an emergency situation, so the media and industry stir concerning the price increase for such a critical device comes as no shock. Since the scandal broke, Mylan accepted overcharging penalties from the U.S. Department of Justice at $465m.
Mylan CEO Heather Breschsaid in her device release statement “Pharmaceutical pricing is too far removed from the patient at the pharmacy counter and not designed for today’s increasingly consumerised healthcare system……….This is why we took decisive action with our EpiPen product and have launched the first generic version at half the WAC price.”
What were your thoughts on the EpiPen price hike and this new product release?
Nicola Lawler, Head of Marketing at Projectus Consulting